The factor (F)VIII K1693N mutation (FVIII-Nara) in a patient with moderate hemophilia A confers resistance to thrombin-catalyzed cleavage at Arg1689 involving P4ʹ position
Journal of Thrombosis and Haemostasis · 2025
DOI: 10.1016/j.jtha.2025.05.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025. Verfasst von Shoko Furukawa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan. Electronic address: sfrkw@naramed-u.ac.jp. Hauptthemen laut MEDLINE: Thrombin, Hemophilia A, Factor VIII, Mutation. Die Arbeit nennt 42 Literaturangaben. Gefördert von: Government of Japan Ministry of Education Culture Sports Science and Technology, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
BACKGROUND: Some patients with nonsevere hemophilia A (HA) are diagnosed with reduced factor (F)VIII activity (FVIII:C) relative to FVIII antigen (FVIII:Ag) and are classified as cross-reactive material-positive. We previously found a novel FVIII-Lys1693Asn (K1693N) natural mutation in a patient with HA with moderate phenotype (FVIII:C/FVIII:Ag = 1.9 IU/dL/124 IU/dL). OBJECTIVE: To examine the mechanism(s) involving the P4' site on thrombin cleavage site at Arg1689 in a cross-reactive material-positive phenotype. METHODS: FVIII-K1693N and its comparison variant K1693A were analyzed for t thrombin-mediated activation. FVIII-K376N, listed in the HA database due to a similar Lys-to-Asn substitution, was examined with K376A as its comparison. All mutants were expressed in BHK cells. RESULTS: FVIII-K1693N showed delayed cleavage at Arg1689 and low peak FVIII:C, while FVIII-K1693A showed mildly reduced FVIII:C after thrombin activation. Mildly reduced peak FVIII:C and similar cleavage to wild-type was illustrated, however, with the FVIII-K1693A mutation after thrombin activation. These findings indicated that the conversion to Asn at P4' site mediated thrombin resistance. FVIII specific activities of FVIII-K376N and FVIII-K376A were 6.1%/3.1% (one-stage assay) of wild-type, respectively. Thrombin-catalyzed cleavage at Arg372 was comparable to wild-type with both mutants, but thrombin-catalyzed FVIII activation was severely-depressed. Spontaneous decay rates of FVIIIa activity with FVIII-K376N (k = 0.53) and FVIII-K376A (k = 0.99) were greater compared to wild-type (k = 0.32), suggesting that cleavage of P4' site following cleavage at Arg372contributed to A1-A2 domainal interaction. CONCLUSION: Lys1693 and Lys376, both located at P4' sites, are suggested to influence FVIII function via distinct mechanisms, indicating that patient-derived mutations can reveal functional aspects of FVIII activation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan. Electronic address: sfrkw@naramed-u.ac.jp.
- Department of Biochemistry, Jichi Medical University School of Medicine, Tochigi, Japan.
- Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan.
- Division of Pediatrics, Higashiosaka City Medical Center, Osaka, Japan.
Förderung
- Government of Japan Ministry of Education Culture Sports Science and Technology
- Japan Agency for Medical Research and Development
Zitieren
APA
Furukawa, S., Baatartsogt, N., Kawamura, T., Horiuchi, K., Doi, M., Kashiwakura, Y., Ohmori, T., & Nogami, K. (2025). The factor (F)VIII K1693N mutation (FVIII-Nara) in a patient with moderate hemophilia A confers resistance to thrombin-catalyzed cleavage at Arg1689 involving P4ʹ position. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2025.05.002
Vancouver
Furukawa S, Baatartsogt N, Kawamura T, Horiuchi K, Doi M, Kashiwakura Y, et al. The factor (F)VIII K1693N mutation (FVIII-Nara) in a patient with moderate hemophilia A confers resistance to thrombin-catalyzed cleavage at Arg1689 involving P4ʹ position. Journal of Thrombosis and Haemostasis. 2025. doi:10.1016/j.jtha.2025.05.002
BibTeX
@article{Furukawa2025,
author = {Furukawa, Shoko and Baatartsogt, Nemekhbayar and Kawamura, Takeshi and Horiuchi, Kaoru and Doi, Masaaki and Kashiwakura, Yuji and Ohmori, Tsukasa and Nogami, Keiji},
title = {The factor (F)VIII K1693N mutation (FVIII-Nara) in a patient with moderate hemophilia A confers resistance to thrombin-catalyzed cleavage at Arg1689 involving P4ʹ position},
journal = {Journal of Thrombosis and Haemostasis},
year = {2025},
doi = {10.1016/j.jtha.2025.05.002}
}
EUVIMED